RAP-219 Phase 2a Seizure Data and Planned Pivotal Trials Might Change The Case For Investing In Rapport Therapeutics (RAPP)

Rapport Therapeutics recently presented new data and post hoc analyses from its Phase 2a trial of RAP-219 in drug-resistant focal onset seizures at the 2025 American Epilepsy Society Meeting, showing ...
The Reporter

Seizures: Why a specific diagnosis can change everything

(BPT) – Zora had her first seizure when she was only six months old. Her dad, away on a trip, got an urgent call from the neighbor. Zora and her mother had just been rushed to the hospital in an ...

LivaNova to Highlight Real-World Evidence from CORE-VNS Study and New Health Economics Analyses at American Epilepsy Society 2025 Annual Meeting

Eight scientific posters demonstrate significant seizure reduction and improved outcomes with VNS Therapy in patients with Drug-Resistant Epilepsy ...
Healio

Psychogenic nonepileptic seizures in youth warrant ‘repeated psychiatric assessment’

Please provide your email address to receive an email when new articles are posted on . Youth with psychogenic nonepileptic seizures experienced an increased risk for numerous psychiatric disorders ...